Zobrazeno 1 - 10
of 37
pro vyhledávání: '"F, Lanier"'
Autor:
Cox, F. Lanier
Publikováno v:
The Accounting Review, 1947 Oct 01. 22(4), 353-359.
Externí odkaz:
https://www.jstor.org/stable/239674
Autor:
L. Gebuhrer, Sylvie Negrier, C. Bain, Christine Lasset, Marie Favrot, T Philip, Adeline Duc, I. Puisieux, V. Bonadona, Yacine Merrouche, J.-Y. Blay, F. Lanier
Publikováno v:
British Journal of Cancer
HLA phenotypes were characterized for 79 patients with metastatic renal cell carcinoma treated with interleukin 2 (IL-2). HLA-A32 was associated with a clinical response (P = 0.025). The frequency of HLA-A3 and/or A32 was higher among responders than
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::37e1903c2fe9889c888fe7201c574e13
https://doi.org/10.1038/bjc.1997.46
https://doi.org/10.1038/bjc.1997.46
Autor:
M, TROTTER, P F, LANIER
Publikováno v:
Human biology. 17
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::6d01e97fdb7b020e332f20df539e577b
https://pubmed.ncbi.nlm.nih.gov/21015697
https://pubmed.ncbi.nlm.nih.gov/21015697
Autor:
Investigators B. Coronel, Co-Investigators Y. Merrouche, Principal Investigators M. C. Favrot, M. O. Heilman, T. Philip, F. Lanier, R. Moen, J. F. Moskovtchenko, Mercatello A, G. Clapisson, C. R. Franks, Irène Philip, J. Y. Ranchere, S. Negrier, Collaborating Investigators P. Tolstoshev
Publikováno v:
Human Gene Therapy. 3:533-542
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::59c2c74882e0f507d7547698f9865e75
https://doi.org/10.1089/hum.1992.3.5-533
https://doi.org/10.1089/hum.1992.3.5-533
Autor:
A. Mercatello, F. Lanier-Demma, Thierry Philip, P. Saltel, V. Lacroix-Kante, Franck Chauvin, Sylvie Negrier
Publikováno v:
European journal of cancer (Oxford, England : 1990). (10)
By addressing questionnaires to 24 cancer patients candidate to immunotherapy, we evaluated both the effects and the effectiveness of the medical information provided to the patient on their knowledge of the disease and the treatment. Most patients h
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::694cff147b24a8974a4508b32bc7704a
https://pubmed.ncbi.nlm.nih.gov/7488418
https://pubmed.ncbi.nlm.nih.gov/7488418
Autor:
Sylvie Negrier, A. Mercatello, Irène Philip, J. F. Moskovtchenko, I. Tabah, M. Gaspard, R. Oskam, Coronel B, T. Philip, M. Favrot, M. Bret, D. Dorez, F. Lanier, P. Palmer, Y. Merrouche, P. Thiesse
Publikováno v:
Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy. 17(1)
We conducted a Phase II trial using an intensive regimen combining interleukin-2 (IL2), interferon-alfa-2b (IFN), and lymphokine-activated killer (LAK) cells. The aim of this study was to evaluate the toxicity and the efficacy of this combination in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8425049625cfbeb0d84fd5097079e8a5
https://pubmed.ncbi.nlm.nih.gov/7728307
https://pubmed.ncbi.nlm.nih.gov/7728307
Autor:
A. Mercatello, C. Lasset, M. C. Favrot, B. Coronel, J. F. Moskovtchenko, T. Philip, Y. Merrouche, F. Lanier, M. O. Heilmann, J. Y. Blay, S. Negrier, M. Bret
Publikováno v:
Contemporary Research on Renal Cell Carcinoma ISBN: 9783642786112
Approximately one-half of patients with renal carcinoma develop metastases, and these have a median survival of 8 months [6, 11, 12]. Metastatic renal cancer has been considered for the past 20 years as a tumor resistant to conventional therapies, an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5ab87eed367db0460c701049c2610f62
https://doi.org/10.1007/978-3-642-78609-9_7
https://doi.org/10.1007/978-3-642-78609-9_7
Autor:
S, Négrier, A, Mercatello, B, Coronel, F, Lanier, Y, Merrouche, M, Bret, J Y, Blay, C, Lasset, P, Thiesse, C, Carrie
Publikováno v:
Bulletin du cancer. 80(7)
Between October 1987 and June 1992, 244 patients with metastatic renal carcinoma were referred to our Institute. One hundred and sixty-nine were included in immunotherapy protocols. The 40 most recent patients were included in the ongoing multicentri
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::21285aa5e8bacd187dd733b40066dc79
https://pubmed.ncbi.nlm.nih.gov/8204940
https://pubmed.ncbi.nlm.nih.gov/8204940
Autor:
V, Lacroix, F, Lanier
Publikováno v:
Revue de l'infirmiere. 42(4)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::afeeb396fe826d702e901e43070fda2c
https://pubmed.ncbi.nlm.nih.gov/1585106
https://pubmed.ncbi.nlm.nih.gov/1585106
Autor:
V, Lacroix, F, Lanier
Publikováno v:
Revue de l'infirmiere. 42(4)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::7f6c8021db4bd2c6d503772d350c143c
https://pubmed.ncbi.nlm.nih.gov/1585107
https://pubmed.ncbi.nlm.nih.gov/1585107